"目录号: HY-13693
GPCR/G Protein-
Mometasone糠酸盐是游离形式mometasone的原药，与糖皮质素受体有较高亲和力。
Glucocorticoid Receptor
相关产品
Hydrocortisone-Dexamethasone-Mifepristone-Prednisolone-Prednisone-Budesonide-Triamcinolone acetonide-(20S)-Protopanaxatriol-Clobetasol propionate-Fluticasone propionate-AL 082D06-Flunisolide-Fluocinonide-Methylprednisolone-Beclometasone dipropionate-
生物活性
Description
Mometasone furoate, prodrug of the free form mometasone, is a agent with high affinity for the glucocorticoid receptor.IC50 value: Target: glucocorticosteroid receptorMometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma [1]. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low systemic bioavailability and high relative binding affinity for the glucocorticoid receptor are properties of MF that allow for a favourable efficacy and tolerability profile. Inhaled MF has been shown to be an effective and well-tolerated controller medication for those patients with mild, moderate or severe persistent asthma [2].
Clinical Trial
NCT00687531
Merck Sharp & Dohme Corp.
Asthma
November 2006
Phase 4
NCT02110654
First Affiliated Hospital, Sun Yat-Sen University
Sinusitis-Nasal Polyps-Asthma
June 2014
Phase 4
NCT00599027
Merck Sharp & Dohme Corp.
Allergic Rhinitis-Asthma
May 2008
Phase 3
NCT01098071
Merck Sharp & Dohme Corp.
Adenoids
August 2008
Phase 4
NCT01228656
Azidus Brasil
Plaque Psoriasis
September 2006
Phase 2
NCT02495064
Yao Liao-Mianyang Central Hospital
Early Radiation Dermatitis
January 2015
Phase 4
NCT00553891
Merck Sharp & Dohme Corp.
Nasal Obstruction-Adenoids Hypertrophy-Adenoidectomy
May 2006
Phase 4
NCT02588326
University of Florida
Hypersensitivity
July 2017
Phase 1
NCT00468312
Merck Sharp & Dohme Corp.
Seasonal Allergic Rhinitis
March 2007
Phase 3
NCT00556673
Novartis-Merck Sharp & Dohme Corp.
Asthma
October 2007
Phase 2
NCT01470053
Hanlim Pharm. Co., Ltd.
Perennial Allergic Rhinitis
March 2011
Phase 3
NCT01135134
Merck Sharp & Dohme Corp.
Rhinitis, Allergic, Perennial
June 2010
Phase 3
NCT00359216
Merck Sharp & Dohme Corp.
Perennial Allergic Rhinitis-Obstructive Sleep Apnea-Sleep Disorder
May 2006
Phase 4
NCT00779740
Merck Sharp & Dohme Corp.
Rhinitis, Allergic, Perennial
February 1, 2005
Phase 3
NCT00835094
Merck Sharp & Dohme Corp.
Asthma
October 1, 2002
Phase 4
NCT01165424
Merck Sharp & Dohme Corp.
Rhinitis, Allergic, Perennial
April 2010
Phase 3
NCT00358527
Merck Sharp & Dohme Corp.-Integrated Therapeutics Group
Seasonal Allergic Rhinitis
May 2006
Phase 4
NCT02125253
Amneal Pharmaceuticals, LLC-Novum Pharmaceutical Research Services
Seasonal Allergic Rhinitis
January 2014
Phase 3
NCT02113267
Mogens Bove-Vastra Gotaland Region
Eosinophilic Esophagitis
April 2014
Phase 2
NCT00453063
Merck Sharp & Dohme Corp.
Seasonal Allergic Rhinitis
March 2007
Phase 3
NCT00552032
Merck Sharp & Dohme Corp.
Adenoids Hypertrophy
August 1, 2007
Phase 3
NCT01333410
Mahidol University
Vitiligo
June 2009
Phase 4
NCT01856543
Memorial Sloan Kettering Cancer Center
Invasive Breast Cancer
May 2013
Phase 3
NCT01555151
Novartis Pharmaceuticals-Novartis
Asthma
July 2012
Phase 2
NCT00805155
Perrigo Company
Healthy
February 2004
NCT00491374
Schering-Plough
Perennial Allergic Rhinitis
September 2006
Phase 4
NCT00491504
Merck Sharp & Dohme Corp.
Seasonal Allergic Rhinitis
February 2007
Phase 4
NCT00381485
Merck Sharp & Dohme Corp.-Novartis
Asthma
July 1, 2006
Phase 3
NCT00378378
Merck Sharp & Dohme Corp.
Nasal Polyps
July 2006
Phase 3
NCT00438659
North Central Cancer Treatment Group-National Cancer Institute (NCI)-Alliance for Clinical Trials in Oncology
Breast Cancer-Dermatologic Complications-Radiation Toxicity-Skin Reactions Secondary to Radiation Therapy
August 2007
Phase 3
NCT00442117
Merck Sharp & Dohme Corp.
Asthma
June 2007
Phase 3
NCT00834119
Merck Sharp & Dohme Corp.
Rhinitis, Allergic
September 1, 2003
Phase 4
NCT00605306
Novartis-Merck Sharp & Dohme Corp.
Asthma
January 2008
Phase 2
NCT00817050
Merck Sharp & Dohme Corp.
Allergic Rhinitis
December 1, 2004
Phase 4
NCT00783458
Merck Sharp & Dohme Corp.
Allergic Rhinitis
December 1, 2004
Phase 4
NCT00732368
Merck Sharp & Dohme Corp.
Perennial Allergic Rhinitis
May 1, 2005
Phase 3
NCT00732381
Merck Sharp & Dohme Corp.
Allergic Rhinitis
August 2008
Phase 3
NCT00733005
Merck Sharp & Dohme Corp.
Allergic Rhinitis
July 2008
Phase 3
NCT00731185
Merck Sharp & Dohme Corp.
Nasal Polyps
September 1, 2003
Phase 3
NCT00903721
Merck Sharp & Dohme Corp.
Allergic Rhinitis
November 2008
NCT00728416
Merck Sharp & Dohme Corp.
Allergic Rhinitis
August 2008
Phase 3
NCT01026870
Merck Sharp & Dohme Corp.
Asthma
June 2012
Phase 3
NCT00779545
Merck Sharp & Dohme Corp.
Rhinitis, Allergic, Perennial
April 8, 2004
Phase 2
NCT01502371
Merck Sharp & Dohme Corp.
Asthma
January 2012
Phase 2
NCT01386125
Merck Sharp & Dohme Corp.
Nasal Polyps
June 2011
Phase 3
NCT01523236
Teva Pharmaceuticals USA
Seasonal Allergic Rhinitis
December 2011
Phase 1-Phase 2
NCT01616160
Massachusetts General Hospital-Merck Sharp & Dohme Corp.-Massachusetts Eye and Ear Infirmary
Nasal Polyps
July 2013
Phase 4
NCT01566149
Merck Sharp & Dohme Corp.
Asthma
March 2012
Phase 3
NCT00521599
Merck Sharp & Dohme Corp.
Asthma
May 2007
Phase 4
NCT00746330
Novartis-Schering-Plough
Asthma
August 2008
Phase 2